Headache Management in Portugal: Consensus among the Portuguese Headache and Neurology Societies, the Portuguese Association of General and Family Medicine, and MiGRA
DOI:
https://doi.org/10.20344/amp.22496Keywords:
Headache/diagnosis, Headache/drug therapy, Migraine Disorders/diagnosis, Migraine Disorders/drug therapy, Portugal, Referral and ConsultationAbstract
Headaches are a significant cause of global disability, with migraines ranking second of all conditions in terms of years lived with disability. Most headache patients, including those with migraine, can and should be effectively diagnosed, treated, and managed in primary healthcare settings. This approach not only reduces the disability associated with these conditions but also prevents progression to chronic forms or the development of medication overuse. The establishment of an efficient referral network, involving patient associations and healthcare professionals beyond primary care, is essential to ensure adequate support for more complex cases and to promote population health in a timely and effective manner. These guidelines for diagnosis, treatment, and referral are the result of a consensus among the Portuguese Headache Society, the Portuguese Society of Neurology, the Portuguese Association of Family Medicine, and MiGRA Portugal, the Portuguese association of migraine and headache patients. This document was designed to empower all physicians to contribute effectively to the management of these conditions.
Downloads
References
Peres MF, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, et al. Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: a call to action. Cephalalgia. 2024;44:03331024241267309. DOI: https://doi.org/10.1177/03331024241267309
Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17. DOI: https://doi.org/10.1186/s10194-018-0846-2
Gil-Gouveia R, Miranda R. Indirect costs attributed to headache: a nation-wide survey of an active working population. Cephalalgia. 2022;42:317-25. DOI: https://doi.org/10.1177/03331024211043795
Pereira-Monteiro J. Cefaleias: estudo epidemiológico e clínico numa população urbana. Porto: Universidade do Porto; 1995.
Gil-Gouveia R, Pereira L, Machado S, Parreira E. Organização de serviços de apoio clínico para doentes com cefaleias em Portugal. Sinapse. 2021;21:112-20. DOI: https://doi.org/10.46531/sinapse/GU/200034/2021
Plácido M, Santos B, Chen-Xu J, Paizinho R, Laires P, Gil-Gouveia R. Headache patients’ perspective on access to specialised medical care and preventive treatment in Portugal: a cross-sectional study. Value Heal. 2024;27. DOI: https://doi.org/10.1016/j.jval.2024.10.1604
Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, et al. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22:90. DOI: https://doi.org/10.1186/s10194-021-01305-8
Braschinsky M, Haldre S, Kals M, Iofik A, Kivisild A, Korjas J, et al. Structured education can improve primary-care management of headache: the first empirical evidence, from a controlled interventional study. J Headache Pain. 2016;17:24. DOI: https://doi.org/10.1186/s10194-016-0613-1
Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23:133. DOI: https://doi.org/10.1186/s10194-022-01502-z
Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21:76. DOI: https://doi.org/10.1186/s10194-020-01130-5
Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press; 2001.
Pereira-Monteiro P, Barros J, Esperança P, Fernandes G, Gil Gouveia R, Luzeiro I, et al. Classificação internacional de cefaleias - 3.a ed., tradução portuguesa. Sinapse. 2018;18:1-172.
Sociedade Portuguesa de Cefaleias. Recomendações terapêuticas para cefaleia primárias. 3.a ed. Sinapse. 2021;1:1-104.
Blau JN. Resolution of migraine attacks: sleep and the recovery phase. J Neurol Neurosurg Psychiatry. 1982;45:223-6. DOI: https://doi.org/10.1136/jnnp.45.3.223
Gil-Gouveia R, Martins I. Validation of the Portuguese version of idmigraine. Headache. 2010;50:396-402. DOI: https://doi.org/10.1111/j.1526-4610.2009.01449.x
Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manag. 2021;2021:9919773. DOI: https://doi.org/10.1155/2021/9919773
Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American migraine prevalence and prevention (AMPP) study. Headache. 2016;56:1635-48. DOI: https://doi.org/10.1111/head.12941
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55:S221-35. DOI: https://doi.org/10.1111/head.12601
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2128544. DOI: https://doi.org/10.1001/jamanetworkopen.2021.28544
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81. DOI: https://doi.org/10.1111/j.1468-1331.2009.02748.x
Abu-Arafeh I, Hershey AD, Diener HC, Tassorelli C. Guidelines update: guidelines of the international headache society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - an experience-based update. Cephalalgia. 2023;43:3331024231178239. DOI: https://doi.org/10.1177/03331024231178239
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021-39. DOI: https://doi.org/10.1111/head.14153
Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644-55. DOI: https://doi.org/10.1111/head.12055
Infarmed. Formulário hospitalar nacional de medicamentos. 2006. [consultado 2024 Jul 31]. Disponível em: https://www.infarmed.pt/ web/infarmed/institucional/documentacao_e_informacao/publicacoes/ tematicos/formulario-hospitalar-nacional-de-medicamentos.
Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23:67. DOI: https://doi.org/10.1186/s10194-022-01431-x
Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333- 41. DOI: https://doi.org/10.1111/head.14692
Crystal SC, Robbins MS. Epidemiology of tension-type headache. Curr Pain Headache Rep. 2010;14:449-54. DOI: https://doi.org/10.1007/s11916-010-0146-2
Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia. 2023;43:3331024231201577. DOI: https://doi.org/10.1177/03331024231201577
Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021;21:392-402. DOI: https://doi.org/10.1136/practneurol-2020-002782
The World Health Organization. Atlas of headache disorders and resources in the world 2011. [consultado 2024 Jul 31]. Disponível em:https://iris.who.int/bitstream/handle/10665/44571/9789241564212_eng. pdf.
Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, et al. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain. 2021;22:78. DOI: https://doi.org/10.1186/s10194-021-01265-z
Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49:1028-41. DOI: https://doi.org/10.1111/j.1526-4610.2009.01410.x
Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018;19:10. DOI: https://doi.org/10.1186/s10194-018-0839-1
Gil-Gouveia R. Tratar a enxaqueca em Portugal – (Quando) haverá uma mudança de paradigma? Um apelo à acção. Sinapse. 2024;24:112-3. DOI: https://doi.org/10.46531/sinapse/AP/34/2024
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3-20. DOI: https://doi.org/10.1111/head.12499
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325:2357- 69. DOI: https://doi.org/10.1001/jama.2021.7939
Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4:CD005220. DOI: https://doi.org/10.1002/14651858.CD005220.pub2
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019;59:1158-73. DOI: https://doi.org/10.1111/head.13628
Belvís R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov. 2009;4:70-81. DOI: https://doi.org/10.2174/157488909787002555
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18. DOI: https://doi.org/10.1111/head.13456
Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38:815-32. DOI: https://doi.org/10.1177/0333102418758283
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
